4/16
07:26 am
vrdn
Foghorn Therapeutics appoints Kristian Humer as chief financial officer [Seeking Alpha]
Medium
Report
Foghorn Therapeutics appoints Kristian Humer as chief financial officer [Seeking Alpha]
4/4
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/29
09:00 am
vrdn
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
Medium
Report
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
3/21
10:45 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target lowered by analysts at B. Riley from $29.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target lowered by analysts at B. Riley from $29.00 to $25.00. They now have a "buy" rating on the stock.
3/20
01:34 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
3/6
04:10 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/6
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5
08:10 am
vrdn
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference [Yahoo! Finance]
Medium
Report
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference [Yahoo! Finance]
3/5
08:00 am
vrdn
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Medium
Report
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
2/29
03:42 pm
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
2/29
05:53 am
vrdn
Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
2/28
11:25 am
vrdn
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81% [Yahoo! Finance]
Neutral
Report
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81% [Yahoo! Finance]
2/28
08:17 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
2/28
08:17 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Wedbush from $39.00 to $40.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Wedbush from $39.00 to $40.00. They now have an "outperform" rating on the stock.
2/27
04:36 pm
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/27
04:01 pm
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
2/20
06:55 am
vrdn
Global Thyroid Eye Disease (TED) Treatment Market Research Report 2023-2029: Strategic Recommendations Include Minimally Invasive Surgical Techniques and Expansion into Iron Deficient Regions [Yahoo! Finance]
Low
Report
Global Thyroid Eye Disease (TED) Treatment Market Research Report 2023-2029: Strategic Recommendations Include Minimally Invasive Surgical Techniques and Expansion into Iron Deficient Regions [Yahoo! Finance]
2/20
05:12 am
vrdn
Thyroid Eye Disease Treatment Market Poised for Significant Growth as Demands Surge, States New 2023-2029 Global Industry Forecast [Yahoo! Finance]
Low
Report
Thyroid Eye Disease Treatment Market Poised for Significant Growth as Demands Surge, States New 2023-2029 Global Industry Forecast [Yahoo! Finance]
2/16
08:13 am
vrdn
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer [Yahoo! Finance]
2/16
08:00 am
vrdn
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
Medium
Report
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
2/6
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/30
08:00 am
vrdn
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. and Encourages Investors to Contact the Firm – VRDN
Low
Report
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. and Encourages Investors to Contact the Firm – VRDN